메뉴 건너뛰기




Volumn , Issue , 2012, Pages 121-156

Pharmacogenetics of Adverse Drug Reactions

Author keywords

Adverse drug reactions; Drug response; Pharmacodynamic; Pharmacogenetics; Pharmacogenomics; Pharmacokinetic

Indexed keywords


EID: 84865853480     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470975053.ch2     Document Type: Chapter
Times cited : (2)

References (244)
  • 1
    • 4243776849 scopus 로고    scopus 로고
    • Mechanisms of adverse drug reactions
    • Davies DM, editor. Textbook of Adverse Drug Reactions. Oxford: Oxford University Press; 1991
    • RawlinsMD, Thompson TJ.Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of Adverse Drug Reactions. Oxford: Oxford University Press; 1991.
    • Rawlins, M.D.1    Thompson, T.J.2
  • 2
    • 15944372781 scopus 로고    scopus 로고
    • Clarification of terminology in drug safety
    • Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851-70.
    • (2005) Drug Saf , vol.28 , Issue.10 , pp. 851-870
    • Aronson, J.K.1    Ferner, R.E.2
  • 4
    • 0033569516 scopus 로고    scopus 로고
    • Pharmacogenomics: translating functional genomics into rational therapeutics
    • EvansWE, RellingMV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286(5439): 487-91.
    • (1999) Science , vol.286 , Issue.5439 , pp. 487-491
    • Evans, W.E.1    Relling, M.V.2
  • 5
    • 84965327618 scopus 로고
    • An epitome of current medical literature
    • Anonymous.
    • Anonymous. An epitome of current medical literature. Fabism. Br Med J 1894; 2: E77.
    • (1894) Fabism. Br Med J , vol.2
  • 6
    • 0000616920 scopus 로고
    • Enzymatic deficiency in primaquine-sensitive erythrocytes
    • Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124(3220): 484-5.
    • (1956) Science , vol.124 , Issue.3220 , pp. 484-485
    • Alving, A.S.1    Carson, P.E.2    Flanagan, C.L.3    Ickes, C.E.4
  • 7
    • 0014483527 scopus 로고
    • Drug-induced hemolytic anemia
    • Beutler E. Drug-induced hemolytic anemia. Pharmacol Rev 1969; 21(1): 73-103.
    • (1969) Pharmacol Rev , vol.21 , Issue.1 , pp. 73-103
    • Beutler, E.1
  • 9
    • 84965047512 scopus 로고
    • The relation between dose of succinylcholine and duration of apnea in man
    • Kalow W, Gunn DR. The relation between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther 1957; 120(2): 203-14.
    • (1957) J Pharmacol Exp Ther , vol.120 , Issue.2 , pp. 203-214
    • Kalow, W.1    Gunn, D.R.2
  • 10
    • 0014426144 scopus 로고
    • Untersuchungen zum Polymorphismus der Acetylierung von Isonicotinsaurehydrazid (INH) [Investigations into the polymorphism of acetylation of isonicotinic acid hydrazid (INH)
    • Goedde HW, Schloot W. Untersuchungen zum Polymorphismus der Acetylierung von Isonicotinsaurehydrazid (INH) [Investigations into the polymorphism of acetylation of isonicotinic acid hydrazid (INH).] Med Welt 1968; 51: 2812-21.
    • (1968) Med Welt , vol.51 , pp. 2812-2821
    • Goedde, H.W.1    Schloot, W.2
  • 16
    • 79959503826 scopus 로고    scopus 로고
    • The International HapMap Project
    • The International HapMap Project. Nature 2003; 426(6968): 789-96.
    • (2003) Nature , vol.426 , Issue.6968 , pp. 789-796
  • 18
    • 0031226574 scopus 로고    scopus 로고
    • Genset-Abbott deal heralds pharmacogenomics era
    • Marshall A. Genset-Abbott deal heralds pharmacogenomics era. Nat Biotechnol 1997; 15(9): 829-30.
    • (1997) Nat Biotechnol , vol.15 , Issue.9 , pp. 829-830
    • Marshall, A.1
  • 19
    • 0030690262 scopus 로고    scopus 로고
    • Getting the right drug into the right patient
    • Marshall A. Getting the right drug into the right patient. Nat Biotechnol 1997; 15(12): 1249-52.
    • (1997) Nat Biotechnol , vol.15 , Issue.12 , pp. 1249-1252
    • Marshall, A.1
  • 20
    • 0037068964 scopus 로고    scopus 로고
    • Clinical importance of the cytochromes P450
    • Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360(9340): 1155-62.
    • (2002) Lancet , vol.360 , Issue.9340 , pp. 1155-1162
    • Nebert, D.W.1    Russell, D.W.2
  • 21
    • 70149110672 scopus 로고    scopus 로고
    • Polymorphism of human cytochrome P450 enzymes and its clinical impact
    • Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41(2): 89-295.
    • (2009) Drug Metab Rev , vol.41 , Issue.2 , pp. 89-295
    • Zhou, S.F.1    Liu, J.P.2    Chowbay, B.3
  • 23
    • 0032793249 scopus 로고    scopus 로고
    • Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
    • Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20(8): 342-9.
    • (1999) Trends Pharmacol Sci , vol.20 , Issue.8 , pp. 342-349
    • Ingelman-Sundberg, M.1    Oscarson, M.2    McLellan, R.A.3
  • 24
    • 0028237729 scopus 로고
    • Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians
    • Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270(1): 414-23.
    • (1994) J Pharmacol Exp Ther , vol.270 , Issue.1 , pp. 414-423
    • Shimada, T.1    Yamazaki, H.2    Mimura, M.3    Inui, Y.4    Guengerich, F.P.5
  • 25
    • 36148976077 scopus 로고    scopus 로고
    • Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects
    • Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116(3): 496-526.
    • (2007) Pharmacol Ther , vol.116 , Issue.3 , pp. 496-526
    • Ingelman-Sundberg, M.1    Sim, S.C.2    Gomez, A.3    Rodriguez-Antona, C.4
  • 26
    • 44349105538 scopus 로고    scopus 로고
    • Human Cytochrome P450 (CYP) Allele Nomenclature Committee
    • Home Page
    • Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Home Page. http://www.imm.ki.se/CYPalleles.
  • 27
    • 0029564238 scopus 로고
    • Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
    • Furuya H, Fernandez-Salguero P, GregoryW, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5(6): 389-92.
    • (1995) Pharmacogenetics , vol.5 , Issue.6 , pp. 389-392
    • Furuya, H.1    Fernandez-Salguero, P.2    Gregory, W.3    Taber, H.4    Steward, A.5    Gonzalez, F.J.6    Idle, J.R.7
  • 28
    • 0033608466 scopus 로고    scopus 로고
    • Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    • Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353(9154): 717-9.
    • (1999) Lancet , vol.353 , Issue.9154 , pp. 717-719
    • Aithal, G.P.1    Day, C.P.2    Kesteven, P.J.3    Daly, A.K.4
  • 29
    • 29244482237 scopus 로고    scopus 로고
    • Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance
    • Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44(12): 1209-25.
    • (2005) Clin Pharmacokinet , vol.44 , Issue.12 , pp. 1209-1225
    • Kirchheiner, J.1    Roots, I.2    Goldammer, M.3    Rosenkranz, B.4    Brockmoller, J.5
  • 31
    • 78149470864 scopus 로고    scopus 로고
    • Polymorphisms of human cytochrome P450 2C9 and the functional relevance
    • Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010; 278(2): 165-88.
    • (2010) Toxicology , vol.278 , Issue.2 , pp. 165-188
    • Zhou, S.F.1    Zhou, Z.W.2    Huang, M.3
  • 32
    • 0034638766 scopus 로고    scopus 로고
    • Pharmacogenetics and adverse drug reactions
    • Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356(9242): 1667-71.
    • (2000) Lancet , vol.356 , Issue.9242 , pp. 1667-1671
    • Meyer, U.A.1
  • 33
    • 0029622428 scopus 로고
    • The pharmacogenetics of codeine hypoalgesia
    • Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5(6): 335-46.
    • (1995) Pharmacogenetics , vol.5 , Issue.6 , pp. 335-346
    • Sindrup, S.H.1    Brosen, K.2
  • 37
    • 50849104253 scopus 로고    scopus 로고
    • Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients
    • Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008; 64(9): 871-6.
    • (2008) Eur J Clin Pharmacol , vol.64 , Issue.9 , pp. 871-876
    • Bohanec Grabar, P.1    Rozman, B.2    Tomsic, M.3    Suput, D.4    Logar, D.5    Dolzan, V.6
  • 38
    • 0035875828 scopus 로고    scopus 로고
    • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    • Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15(1): 71-5.
    • (2001) AIDS , vol.15 , Issue.1 , pp. 71-75
    • Marzolini, C.1    Telenti, A.2    Decosterd, L.A.3    Greub, G.4    Biollaz, J.5    Buclin, T.6
  • 41
    • 0034967764 scopus 로고    scopus 로고
    • Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions
    • Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96(6): 1698-703.
    • (2001) Am J Gastroenterol , vol.96 , Issue.6 , pp. 1698-1703
    • Wysowski, D.K.1    Corken, A.2    Gallo-Torres, H.3    Talarico, L.4    Rodriguez, E.M.5
  • 42
    • 0032815783 scopus 로고    scopus 로고
    • Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
    • Madani S, Paine MF, Lewis L, Thummel KE, Shen DD. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 1999; 16(8): 1199-205.
    • (1999) Pharm Res , vol.16 , Issue.8 , pp. 1199-1205
    • Madani, S.1    Paine, M.F.2    Lewis, L.3    Thummel, K.E.4    Shen, D.D.5
  • 44
    • 33748787999 scopus 로고    scopus 로고
    • Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
    • Sep
    • Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006 Sep; 58(3): 521-90.
    • (2006) Pharmacol Rev , vol.58 , Issue.3 , pp. 521-590
    • Gardiner, S.J.1    Begg, E.J.2
  • 45
    • 13544249943 scopus 로고    scopus 로고
    • Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
    • Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5(1): 6-13.
    • (2005) Pharmacogenomics J , vol.5 , Issue.1 , pp. 6-13
    • Ingelman-Sundberg, M.1
  • 48
    • 35549000170 scopus 로고    scopus 로고
    • The pharmacogenetics of analgesia
    • Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007; 8(14): 2235-45.
    • (2007) Expert Opin Pharmacother , vol.8 , Issue.14 , pp. 2235-2245
    • Stamer, U.M.1    Stuber, F.2
  • 51
    • 57749180179 scopus 로고    scopus 로고
    • Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study
    • Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009; 85(1): 31-5.
    • (2009) Clin Pharmacol Ther , vol.85 , Issue.1 , pp. 31-35
    • Madadi, P.1    Ross, C.J.2    Hayden, M.R.3    Carleton, B.C.4    Gaedigk, A.5    Leeder, J.S.6    Koren, G.7
  • 53
    • 33749027737 scopus 로고    scopus 로고
    • Can pharmacogenetics help rescue drugs withdrawn from the market?
    • Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006; 7(6): 889-908.
    • (2006) Pharmacogenomics , vol.7 , Issue.6 , pp. 889-908
    • Shah, R.R.1
  • 54
    • 0036263813 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
    • Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12(3): 251-63.
    • (2002) Pharmacogenetics , vol.12 , Issue.3 , pp. 251-263
    • Lee, C.R.1    Goldstein, J.A.2    Pieper, J.A.3
  • 55
    • 77951898626 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin
    • Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010; 61: 63-75.
    • (2010) Annu Rev Med , vol.61 , pp. 63-75
    • Kamali, F.1    Wynne, H.2
  • 57
    • 34147162376 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin: current status and future challenges
    • Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7(2): 99-111.
    • (2007) Pharmacogenomics J , vol.7 , Issue.2 , pp. 99-111
    • Wadelius, M.1    Pirmohamed, M.2
  • 59
    • 0033884635 scopus 로고    scopus 로고
    • Cytochrome P450 polymorphisms are associated with reduced warfarin dose
    • Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128(2): 281-5.
    • (2000) Surgery , vol.128 , Issue.2 , pp. 281-285
    • Freeman, B.D.1    Zehnbauer, B.A.2    McGrath, S.3    Borecki, I.4    Buchman, T.G.5
  • 62
    • 62549143945 scopus 로고    scopus 로고
    • Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis
    • Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur J Clin Pharmacol 2009; 65(4): 365-75.
    • (2009) Eur J Clin Pharmacol , vol.65 , Issue.4 , pp. 365-375
    • Lindh, J.D.1    Holm, L.2    Andersson, M.L.3    Rane, A.4
  • 63
    • 11244332058 scopus 로고    scopus 로고
    • A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
    • D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105(2): 645-9.
    • (2005) Blood , vol.105 , Issue.2 , pp. 645-649
    • D'Andrea, G.1    D'Ambrosio, R.L.2    Di Perna, P.3    Chetta, M.4    Santacroce, R.5    Brancaccio, V.6    Grandone, E.7    Margaglione, M.8
  • 64
    • 12344331747 scopus 로고    scopus 로고
    • Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1
    • Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93(1): 23-6.
    • (2005) Thromb Haemost , vol.93 , Issue.1 , pp. 23-26
    • Harrington, D.J.1    Underwood, S.2    Morse, C.3    Shearer, M.J.4    Tuddenham, E.G.5    Mumford, A.D.6
  • 67
    • 18844444813 scopus 로고    scopus 로고
    • Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation
    • Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93(5): 872-5.
    • (2005) Thromb Haemost , vol.93 , Issue.5 , pp. 872-875
    • Sconce, E.1    Khan, T.2    Mason, J.3    Noble, F.4    Wynne, H.5    Kamali, F.6
  • 69
    • 23044440450 scopus 로고    scopus 로고
    • The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
    • Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106(7): 2329-33.
    • (2005) Blood , vol.106 , Issue.7 , pp. 2329-2333
    • Sconce, E.A.1    Khan, T.I.2    Wynne, H.A.3    Avery, P.4    Monkhouse, L.5    King, B.P.6    Wood, P.7    Kesteven, P.8    Daly, A.K.9    Kamali, F.10
  • 70
    • 38049181030 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues
    • Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25(1): 45-51.
    • (2008) J Thromb Thrombolysis , vol.25 , Issue.1 , pp. 45-51
    • Gage, B.F.1    Lesko, L.J.2
  • 73
    • 0030739223 scopus 로고    scopus 로고
    • Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation
    • Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 1997; 25(8): 985-93.
    • (1997) Drug Metab Dispos , vol.25 , Issue.8 , pp. 985-993
    • Code, E.L.1    Crespi, C.L.2    Penman, B.W.3    Gonzalez, F.J.4    Chang, T.K.5    Waxman, D.J.6
  • 80
    • 0035369825 scopus 로고    scopus 로고
    • Genetic susceptibility to adverse drug reactions
    • Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22(6): 298-305.
    • (2001) Trends Pharmacol Sci , vol.22 , Issue.6 , pp. 298-305
    • Pirmohamed, M.1    Park, B.K.2
  • 81
    • 0018822866 scopus 로고
    • Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity
    • Weinshilboum RM, Sladek SL.Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32(5): 651-62.
    • (1980) Am J Hum Genet , vol.32 , Issue.5 , pp. 651-662
    • Weinshilboum, R.M.1    Sladek, S.L.2
  • 82
    • 0025331198 scopus 로고
    • Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
    • Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336(8709): 225-9.
    • (1990) Lancet , vol.336 , Issue.8709 , pp. 225-229
    • Lennard, L.1    Lilleyman, J.S.2    Van Loon, J.3    Weinshilboum, R.M.4
  • 88
    • 0028902661 scopus 로고
    • Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis
    • Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol 1995; 39(4): 411-15.
    • (1995) Br J Clin Pharmacol , vol.39 , Issue.4 , pp. 411-415
    • Green, V.J.1    Pirmohamed, M.2    Kitteringham, N.R.3    Knapp, M.J.4    Park, B.K.5
  • 91
    • 33947590154 scopus 로고    scopus 로고
    • Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors
    • Oldenburg J, Kraggerud SM, CvancarovaM, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25(6): 708-14.
    • (2007) J Clin Oncol , vol.25 , Issue.6 , pp. 708-714
    • Oldenburg, J.1    Kraggerud, S.M.2    Cvancarova, M.3    Lothe, R.A.4    Fossa, S.D.5
  • 92
    • 0036009619 scopus 로고    scopus 로고
    • The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics
    • McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3(1): 89-98.
    • (2002) Pharmacogenomics , vol.3 , Issue.1 , pp. 89-98
    • McLeod, H.L.1    Siva, C.2
  • 93
    • 33645119580 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions
    • Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25(11): 1629-38.
    • (2006) Oncogene , vol.25 , Issue.11 , pp. 1629-1638
    • Wang, L.1    Weinshilboum, R.2
  • 94
    • 54049121096 scopus 로고    scopus 로고
    • Highly multiplexed genotyping of thiopurine s-methyltransferase variants usingMALD-TOFmass spectrometry: reliable genotyping in different ethnic groups
    • Schaeffeler E, Zanger UM, EichelbaumM, Asante-Poku S, Shin JG, SchwabM. Highly multiplexed genotyping of thiopurine s-methyltransferase variants usingMALD-TOFmass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 2008; 54(10): 1637-47.
    • (2008) Clin Chem , vol.54 , Issue.10 , pp. 1637-1647
    • Schaeffeler, E.1    Zanger, U.M.2    Eichelbaum, M.3    Asante-Poku, S.4    Shin, J.G.5    Schwab, M.6
  • 96
    • 40049089901 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore
    • Kham SK, Soh CK, Liu TC, Chan YH, Ariffin H, Tan PL, Yeoh AE. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol 2008; 64(4): 373-9.
    • (2008) Eur J Clin Pharmacol , vol.64 , Issue.4 , pp. 373-379
    • Kham, S.K.1    Soh, C.K.2    Liu, T.C.3    Chan, Y.H.4    Ariffin, H.5    Tan, P.L.6    Yeoh, A.E.7
  • 97
    • 2542465496 scopus 로고    scopus 로고
    • Food andDrugAdministration
    • Center forDrugEvaluation and Research.Meeting of the Pediatric Subcommittee of theOncologicDrugs Advisory Committee
    • Food andDrugAdministration. Center forDrugEvaluation and Research.Meeting of the Pediatric Subcommittee of theOncologicDrugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3971T1.htm.
  • 98
    • 33947357078 scopus 로고    scopus 로고
    • Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription
    • Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Bruce I, Payne K. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32(2): 187-95.
    • (2007) J Clin Pharm Ther , vol.32 , Issue.2 , pp. 187-195
    • Fargher, E.A.1    Tricker, K.2    Newman, W.3    Elliott, R.4    Roberts, S.A.5    Shaffer, J.L.6    Bruce, I.7    Payne, K.8
  • 99
    • 0033760290 scopus 로고    scopus 로고
    • Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance
    • Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000; 38(9): 889-92.
    • (2000) Clin Chem Lab Med , vol.38 , Issue.9 , pp. 889-892
    • Mackenzie, P.I.1    Miners, J.O.2    McKinnon, R.A.3
  • 100
    • 0035884212 scopus 로고    scopus 로고
    • Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel
    • Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19(18): 3801-7.
    • (2001) J Clin Oncol , vol.19 , Issue.18 , pp. 3801-3807
    • Rothenberg, M.L.1    Meropol, N.J.2    Poplin, E.A.3    Van Cutsem, E.4    Wadler, S.5
  • 101
    • 33750583902 scopus 로고    scopus 로고
    • Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy
    • O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006; 24(28): 4534-8.
    • (2006) J Clin Oncol , vol.24 , Issue.28 , pp. 4534-4538
    • O'Dwyer, P.J.1    Catalano, R.B.2
  • 105
    • 73349138231 scopus 로고    scopus 로고
    • UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
    • Schulz C, Boeck S, Heinemann V, Stemmler HJ. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 2009; 20(10): 867-79.
    • (2009) Anticancer Drugs , vol.20 , Issue.10 , pp. 867-879
    • Schulz, C.1    Boeck, S.2    Heinemann, V.3    Stemmler, H.J.4
  • 107
    • 24344439264 scopus 로고    scopus 로고
    • Transporters and drug therapy: implications for drug disposition and disease
    • Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78(3): 260-77.
    • (2005) Clin Pharmacol Ther , vol.78 , Issue.3 , pp. 260-277
    • Ho, R.H.1    Kim, R.B.2
  • 108
    • 70350048926 scopus 로고    scopus 로고
    • Impact of OATP transporters on pharmacokinetics
    • Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158(3): 693-705.
    • (2009) Br J Pharmacol , vol.158 , Issue.3 , pp. 693-705
    • Kalliokoski, A.1    Niemi, M.2
  • 111
    • 73449131555 scopus 로고    scopus 로고
    • Prolonged neutropenia after irinotecanbased chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1
    • Sakaguchi S, Garcia-Bournissen F, Kim R, SchwarzUI, Nathan PC, Ito S. Prolonged neutropenia after irinotecanbased chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Arch Dis Child 2009; 94(12): 981-2.
    • (2009) Arch Dis Child , vol.94 , Issue.12 , pp. 981-982
    • Sakaguchi, S.1    Garcia-Bournissen, F.2    Kim, R.3    Schwarz, U.I.4    Nathan, P.C.5    Ito, S.6
  • 112
    • 63949084512 scopus 로고    scopus 로고
    • Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy
    • Takane H, Kawamoto K, Sasaki T, Moriki K, KitanoH, Higuchi S, Otsubo K, Ieiri I. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 2009; 63(6): 1165-9.
    • (2009) Cancer Chemother Pharmacol , vol.63 , Issue.6 , pp. 1165-1169
    • Takane, H.1    Kawamoto, K.2    Sasaki, T.3    Moriki, K.4    Kitano, H.5    Higuchi, S.6    Otsubo, K.7    Ieiri, I.8
  • 113
    • 0038106665 scopus 로고    scopus 로고
    • Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs
    • Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4(4): 397-410.
    • (2003) Pharmacogenomics , vol.4 , Issue.4 , pp. 397-410
    • Sakaeda, T.1    Nakamura, T.2    Okumura, K.3
  • 118
    • 33846230114 scopus 로고    scopus 로고
    • Genetic susceptibility to diclofenacinduced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes
    • Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenacinduced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132(1): 272-81.
    • (2007) Gastroenterology , vol.132 , Issue.1 , pp. 272-281
    • Daly, A.K.1    Aithal, G.P.2    Leathart, J.B.3    Swainsbury, R.A.4    Dang, T.S.5    Day, C.P.6
  • 121
    • 40949126593 scopus 로고    scopus 로고
    • Global analysis of genetic variation in SLCO1B1
    • Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008; 9(1): 19-33.
    • (2008) Pharmacogenomics , vol.9 , Issue.1 , pp. 19-33
    • Pasanen, M.K.1    Neuvonen, P.J.2    Niemi, M.3
  • 122
    • 2042469487 scopus 로고    scopus 로고
    • Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
    • Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004; 75(5): 415-21.
    • (2004) Clin Pharmacol Ther , vol.75 , Issue.5 , pp. 415-421
    • Mwinyi, J.1    Johne, A.2    Bauer, S.3    Roots, I.4    Gerloff, T.5
  • 124
    • 42149127614 scopus 로고    scopus 로고
    • The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15
    • Deng JW, Song IS, Shin HJ, Yeo CW, Cho DY, Shon JH, Shin JG. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 2008; 18(5): 424-33.
    • (2008) Pharmacogenet Genomics , vol.18 , Issue.5 , pp. 424-433
    • Deng, J.W.1    Song, I.S.2    Shin, H.J.3    Yeo, C.W.4    Cho, D.Y.5    Shon, J.H.6    Shin, J.G.7
  • 125
    • 36148953896 scopus 로고    scopus 로고
    • Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
    • Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82(6): 726-33.
    • (2007) Clin Pharmacol Ther , vol.82 , Issue.6 , pp. 726-733
    • Pasanen, M.K.1    Fredrikson, H.2    Neuvonen, P.J.3    Niemi, M.4
  • 126
    • 33751096467 scopus 로고    scopus 로고
    • SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
    • Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16(12): 873-9.
    • (2006) Pharmacogenet Genomics , vol.16 , Issue.12 , pp. 873-879
    • Pasanen, M.K.1    Neuvonen, M.2    Neuvonen, P.J.3    Niemi, M.4
  • 127
    • 33749049136 scopus 로고    scopus 로고
    • SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
    • Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80(4): 356-66.
    • (2006) Clin Pharmacol Ther , vol.80 , Issue.4 , pp. 356-366
    • Niemi, M.1    Pasanen, M.K.2    Neuvonen, P.J.3
  • 128
    • 33846568546 scopus 로고    scopus 로고
    • ABCB1 pharmacogenetics: progress, pitfalls, and promise
    • Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007; 81(2): 265-9.
    • (2007) Clin Pharmacol Ther , vol.81 , Issue.2 , pp. 265-269
    • Chinn, L.W.1    Kroetz, D.L.2
  • 129
    • 42949143111 scopus 로고    scopus 로고
    • Genetic variations and gene expression of transporters in drug disposition and response
    • Huang Y, Penchala S, Pham AN, Wang J. Genetic variations and gene expression of transporters in drug disposition and response. Expert Opin Drug Metab Toxicol 2008; 4(3): 237-54.
    • (2008) Expert Opin Drug Metab Toxicol , vol.4 , Issue.3 , pp. 237-254
    • Huang, Y.1    Penchala, S.2    Pham, A.N.3    Wang, J.4
  • 131
    • 12344334846 scopus 로고    scopus 로고
    • Clinical aspects of the MDR1 (ABCB1) gene polymorphism
    • Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26(2): 180-5.
    • (2004) Ther Drug Monit , vol.26 , Issue.2 , pp. 180-185
    • Eichelbaum, M.1    Fromm, M.F.2    Schwab, M.3
  • 133
    • 23044491475 scopus 로고    scopus 로고
    • Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression
    • Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 2005; 60(2): 159-71.
    • (2005) Br J Clin Pharmacol , vol.60 , Issue.2 , pp. 159-171
    • Chowbay, B.1    Li, H.2    David, M.3    Cheung, Y.B.4    Lee, E.J.5
  • 134
    • 18144399975 scopus 로고    scopus 로고
    • Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation
    • Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 2005; 6(2): 163-8.
    • (2005) Pharmacogenomics , vol.6 , Issue.2 , pp. 163-168
    • Szekeres, T.1    Haushofer, A.2
  • 135
    • 48949119314 scopus 로고    scopus 로고
    • A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine
    • Hesselink DA, van Schaik RH, Nauta J, van Gelder T. A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics 2008; 9(6): 783-9.
    • (2008) Pharmacogenomics , vol.9 , Issue.6 , pp. 783-789
    • Hesselink, D.A.1    van Schaik, R.H.2    Nauta, J.3    van Gelder, T.4
  • 138
    • 0028914969 scopus 로고
    • A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
    • Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80(5): 795-803.
    • (1995) Cell , vol.80 , Issue.5 , pp. 795-803
    • Curran, M.E.1    Splawski, I.2    Timothy, K.W.3    Vincent, G.M.4    Green, E.D.5    Keating, M.T.6
  • 140
    • 1442306232 scopus 로고    scopus 로고
    • Drug-induced prolongation of the QT interval
    • Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350(10): 1013-22.
    • (2004) N Engl J Med , vol.350 , Issue.10 , pp. 1013-1022
    • Roden, D.M.1
  • 141
    • 0030903368 scopus 로고    scopus 로고
    • Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
    • Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2(2): 139-45.
    • (1997) Mol Psychiatry , vol.2 , Issue.2 , pp. 139-145
    • Steen, V.M.1    Lovlie, R.2    MacEwan, T.3    McCreadie, R.G.4
  • 142
    • 0030975438 scopus 로고    scopus 로고
    • Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia
    • Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41(7): 827-9.
    • (1997) Biol Psychiatry , vol.41 , Issue.7 , pp. 827-829
    • Chen, C.H.1    Wei, F.C.2    Koong, F.J.3    Hsiao, K.J.4
  • 144
    • 0036371340 scopus 로고    scopus 로고
    • Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia
    • Zhang ZJ, Zhang XB, Sha WW, Reynolds GP. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002; 7(7): 670-1.
    • (2002) Mol Psychiatry , vol.7 , Issue.7 , pp. 670-671
    • Zhang, Z.J.1    Zhang, X.B.2    Sha, W.W.3    Reynolds, G.P.4
  • 145
    • 17644394540 scopus 로고    scopus 로고
    • Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis
    • Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15(4): 195-200.
    • (2005) Pharmacogenet Genomics , vol.15 , Issue.4 , pp. 195-200
    • Templeman, L.A.1    Reynolds, G.P.2    Arranz, B.3    San, L.4
  • 147
    • 0031033922 scopus 로고    scopus 로고
    • Fc gamma RIIA H/R 131 polymorphism, subclassspecific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis
    • Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H/R 131 polymorphism, subclassspecific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997; 89(2): 370-5.
    • (1997) Blood , vol.89 , Issue.2 , pp. 370-375
    • Arepally, G.1    McKenzie, S.E.2    Jiang, X.M.3    Poncz, M.4    Cines, D.B.5
  • 148
    • 0031687887 scopus 로고    scopus 로고
    • A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity
    • Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64(3): 169-72.
    • (1998) Mol Genet Metab , vol.64 , Issue.3 , pp. 169-172
    • Weisberg, I.1    Tran, P.2    Christensen, B.3    Sibani, S.4    Rozen, R.5
  • 150
    • 0034942087 scopus 로고    scopus 로고
    • The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage
    • Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med 2001; 95(2): 130-5.
    • (2001) Respir Med , vol.95 , Issue.2 , pp. 130-135
    • Takahashi, T.1    Yamaguchi, E.2    Furuya, K.3    Kawakami, Y.4
  • 151
    • 0033858856 scopus 로고    scopus 로고
    • Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough
    • Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000; 36(1): 127-31.
    • (2000) Hypertension , vol.36 , Issue.1 , pp. 127-131
    • Mukae, S.1    Aoki, S.2    Itoh, S.3    Iwata, T.4    Ueda, H.5    Katagiri, T.6
  • 152
    • 0036959461 scopus 로고    scopus 로고
    • Association of polymorphisms of the reninangiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough
    • Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T. Association of polymorphisms of the reninangiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 2002; 16(12): 857-63.
    • (2002) J Hum Hypertens , vol.16 , Issue.12 , pp. 857-863
    • Mukae, S.1    Itoh, S.2    Aoki, S.3    Iwata, T.4    Nishio, K.5    Sato, R.6    Katagiri, T.7
  • 153
    • 72849146368 scopus 로고    scopus 로고
    • Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction
    • Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem 2010; 112(2): 486-96.
    • (2010) J Neurochem , vol.112 , Issue.2 , pp. 486-496
    • Deb, I.1    Chakraborty, J.2    Gangopadhyay, P.K.3    Choudhury, S.R.4    Das, S.5
  • 159
    • 18044396715 scopus 로고    scopus 로고
    • Pharmacogenomics and acquired long QT syndrome
    • Aerssens J, Paulussen AD. Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 2005; 6(3): 259-70.
    • (2005) Pharmacogenomics , vol.6 , Issue.3 , pp. 259-270
    • Aerssens, J.1    Paulussen, A.D.2
  • 160
    • 12844265304 scopus 로고    scopus 로고
    • An underrecognized challenge in evaluating postmarketing drug safety
    • Roden DM. An underrecognized challenge in evaluating postmarketing drug safety. Circulation 2005; 111(3): 246-8.
    • (2005) Circulation , vol.111 , Issue.3 , pp. 246-248
    • Roden, D.M.1
  • 161
    • 33646944093 scopus 로고    scopus 로고
    • Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
    • Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21(5): 589-98.
    • (2006) Mov Disord , vol.21 , Issue.5 , pp. 589-598
    • Tarsy, D.1    Baldessarini, R.J.2
  • 162
    • 33746522294 scopus 로고    scopus 로고
    • An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
    • McEvoy JP. An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr 2006; 11(7 Suppl 7): 4-8.
    • (2006) CNS Spectr , vol.11 , Issue.7 SUPPL. , pp. 4-8
    • McEvoy, J.P.1
  • 163
    • 55449133424 scopus 로고    scopus 로고
    • Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics
    • Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9(9): 1285-306.
    • (2008) Pharmacogenomics , vol.9 , Issue.9 , pp. 1285-1306
    • Thelma, B.1    Srivastava, V.2    Tiwari, A.K.3
  • 165
    • 0036342556 scopus 로고    scopus 로고
    • Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics
    • Woo SI, Kim JW, Rha E, Han SH, Hahn KH, Park CS, Sohn JW. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 2002; 56(4): 469-74.
    • (2002) Psychiatry Clin Neurosci , vol.56 , Issue.4 , pp. 469-474
    • Woo, S.I.1    Kim, J.W.2    Rha, E.3    Han, S.H.4    Hahn, K.H.5    Park, C.S.6    Sohn, J.W.7
  • 166
    • 0030598907 scopus 로고    scopus 로고
    • Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system
    • Lundstrom K, Turpin MP. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996; 225(3): 1068-72.
    • (1996) Biochem Biophys Res Commun , vol.225 , Issue.3 , pp. 1068-1072
    • Lundstrom, K.1    Turpin, M.P.2
  • 168
    • 2342562985 scopus 로고    scopus 로고
    • Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients
    • Liou YJ, Wang YC, Bai YM, Lin CC, Yu SC, Liao DL, Lin MW, Chen JY, Lai IC. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004; 49(4): 167-73.
    • (2004) Neuropsychobiology , vol.49 , Issue.4 , pp. 167-173
    • Liou, Y.J.1    Wang, Y.C.2    Bai, Y.M.3    Lin, C.C.4    Yu, S.C.5    Liao, D.L.6    Lin, M.W.7    Chen, J.Y.8    Lai, I.C.9
  • 169
    • 42349094914 scopus 로고    scopus 로고
    • Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions
    • Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13(5): 544-56.
    • (2008) Mol Psychiatry , vol.13 , Issue.5 , pp. 544-556
    • Bakker, P.R.1    van Harten, P.N.2    van Os, J.3
  • 170
    • 36049025851 scopus 로고    scopus 로고
    • The impact of pharmacogenetics on the development and use of antipsychotic drugs
    • Reynolds GP. The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov Today 2007; 12(21-22): 953-9.
    • (2007) Drug Discov Today , vol.12 , Issue.21-22 , pp. 953-959
    • Reynolds, G.P.1
  • 171
    • 33845341401 scopus 로고    scopus 로고
    • Susceptibility genes for the side effect of antipsychotics on body weight and obesity
    • Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006; 7(12): 1681-95.
    • (2006) Curr Drug Targets , vol.7 , Issue.12 , pp. 1681-1695
    • Chagnon, Y.C.1
  • 172
    • 0034103054 scopus 로고    scopus 로고
    • Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes
    • Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43(3): 373-6.
    • (2000) Diabetologia , vol.43 , Issue.3 , pp. 373-376
    • Yuan, X.1    Yamada, K.2    Ishiyama-Shigemoto, S.3    Koyama, W.4    Nonaka, K.5
  • 173
    • 11244270333 scopus 로고    scopus 로고
    • A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses
    • Chagnon YC, Merette C, Bouchard RH, Emond C, Roy MA, Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004; 9(12): 1067-74.
    • (2004) Mol Psychiatry , vol.9 , Issue.12 , pp. 1067-1074
    • Chagnon, Y.C.1    Merette, C.2    Bouchard, R.H.3    Emond, C.4    Roy, M.A.5    Maziade, M.6
  • 174
    • 36749070913 scopus 로고    scopus 로고
    • Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine
    • Chagnon YC, Bureau A, Gendron D, Bouchard RH, Merette C, Roy MA, Maziade M. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am J Med Genet B Neuropsychiatr Genet 2007; 144B(8): 1063-9.
    • (2007) Am J Med Genet B Neuropsychiatr Genet , vol.144 , Issue.8 , pp. 1063-1069
    • Chagnon, Y.C.1    Bureau, A.2    Gendron, D.3    Bouchard, R.H.4    Merette, C.5    Roy, M.A.6    Maziade, M.7
  • 175
  • 177
    • 44949234553 scopus 로고    scopus 로고
    • Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
    • Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008; 9(5): 511-26.
    • (2008) Pharmacogenomics , vol.9 , Issue.5 , pp. 511-526
    • Limdi, N.A.1    Arnett, D.K.2    Goldstein, J.A.3    Beasley, T.M.4    McGwin, G.5    Adler, B.K.6    Acton, R.T.7
  • 182
    • 0031719374 scopus 로고    scopus 로고
    • Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective
    • Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11(9): 969-88.
    • (1998) Chem Res Toxicol , vol.11 , Issue.9 , pp. 969-988
    • Park, B.K.1    Pirmohamed, M.2    Kitteringham, N.R.3
  • 183
    • 33645815444 scopus 로고    scopus 로고
    • Genetic factors in the predisposition to drug-induced hypersensitivity reactions
    • PirmohamedM. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 2006; 8(1): E20-6.
    • (2006) AAPS J , vol.8 , Issue.1
    • Pirmohamed, M.1
  • 185
    • 0037006623 scopus 로고    scopus 로고
    • Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
    • Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359(9308): 727-32.186. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982): 486.
    • (2002) Lancet , vol.359 , Issue.9308 , pp. 727-732
    • Mallal, S.1    Nolan, D.2    Witt, C.3    Masel, G.4    Martin, A.M.5    Moore, C.6    Sayer, D.7    Castley, A.8    Mamotte, C.9    Maxwell, D.10    James, I.11    Christiansen, F.T.12
  • 188
    • 0025175183 scopus 로고
    • HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia
    • Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990; 47(10): 945-8.
    • (1990) Arch Gen Psychiatry , vol.47 , Issue.10 , pp. 945-948
    • Lieberman, J.A.1    Yunis, J.2    Egea, E.3    Canoso, R.T.4    Kane, J.M.5    Yunis, E.J.6
  • 189
    • 34748816239 scopus 로고    scopus 로고
    • Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens
    • Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007; 7(5): 325-32.
    • (2007) Pharmacogenomics J , vol.7 , Issue.5 , pp. 325-332
    • Dettling, M.1    Cascorbi, I.2    Opgen-Rhein, C.3    Schaub, R.4
  • 190
  • 198
    • 0025303320 scopus 로고
    • HLA-B27 and agranulocytosis by levamisole
    • Diez RA. HLA-B27 and agranulocytosis by levamisole. Immunol Today 1990; 11(8): 270.
    • (1990) Immunol Today , vol.11 , Issue.8 , pp. 270
    • Diez, R.A.1
  • 200
    • 34248589506 scopus 로고    scopus 로고
    • Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
    • Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48(5): 1015-18.
    • (2007) Epilepsia , vol.48 , Issue.5 , pp. 1015-1018
    • Man, C.B.1    Kwan, P.2    Baum, L.3    Yu, E.4    Lau, K.M.5    Cheng, A.S.6    Ng, M.H.7
  • 206
    • 33745295856 scopus 로고    scopus 로고
    • Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study
    • Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43(1): 99-102.
    • (2006) Clin Infect Dis , vol.43 , Issue.1 , pp. 99-102
    • Rauch, A.1    Nolan, D.2    Martin, A.3    McKinnon, E.4    Almeida, C.5    Mallal, S.6
  • 207
    • 34247636623 scopus 로고    scopus 로고
    • Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population
    • Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45(1): 1-3.
    • (2007) J Acquir Immune Defic Syndr , vol.45 , Issue.1 , pp. 1-3
    • Zucman, D.1    Truchis, P.2    Majerholc, C.3    Stegman, S.4    Caillat-Zucman, S.5
  • 208
    • 3042634326 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
    • Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14(6): 335-42.
    • (2004) Pharmacogenetics , vol.14 , Issue.6 , pp. 335-342
    • Hughes, D.A.1    Vilar, F.J.2    Ward, C.C.3    Alfirevic, A.4    Park, B.K.5    Pirmohamed, M.6
  • 212
    • 84886183600 scopus 로고    scopus 로고
    • DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - AWorking Group of the Office of AIDS Research Advisory Council (OARAC)
    • Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 1 December 2009
    • DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - AWorking Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 1 December 2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
  • 213
    • 42449120613 scopus 로고    scopus 로고
    • Pharmacogenetic information derived from analysis of HLA alleles
    • Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008; 9(2): 207-14.
    • (2008) Pharmacogenomics , vol.9 , Issue.2 , pp. 207-214
    • Gatanaga, H.1    Honda, H.2    Oka, S.3
  • 214
    • 0028793442 scopus 로고
    • Anticonvulsant hypersensitivity syndrome
    • Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155(21): 2285-90.
    • (1995) Arch Intern Med , vol.155 , Issue.21 , pp. 2285-2290
    • Vittorio, C.C.1    Muglia, J.J.2
  • 223
    • 77956550478 scopus 로고    scopus 로고
    • International Serious Adverse Events Consortium
    • International Serious Adverse Events Consortium. http://www.saeconsortium.org/.
  • 224
    • 0037374498 scopus 로고    scopus 로고
    • The price of innovation: new estimates of drug development costs
    • DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22(2): 151-85.
    • (2003) J Health Econ , vol.22 , Issue.2 , pp. 151-185
    • DiMasi, J.A.1    Hansen, R.W.2    Grabowski, H.G.3
  • 225
    • 4344684441 scopus 로고    scopus 로고
    • Pharmacogenetics and drug development: the path to safer and more effective drugs
    • Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5(9): 645-56.
    • (2004) Nat Rev Genet , vol.5 , Issue.9 , pp. 645-656
    • Roses, A.D.1
  • 226
    • 0035056821 scopus 로고    scopus 로고
    • Pharmacogenetic application in drug development and clinical trials
    • Shi MM, Bleavins MR, de la Iglesia FA. Pharmacogenetic application in drug development and clinical trials. Drug Metab Dispos 2001; 29(4 Pt 2): 591-5.
    • (2001) Drug Metab Dispos , vol.29 , Issue.4 , pp. 591-595
    • Shi, M.M.1    Bleavins, M.R.2    de la Iglesia, F.A.3
  • 227
    • 53249118974 scopus 로고    scopus 로고
    • Pharmacogenetics in drug discovery and development: a translational perspective
    • Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008; 7(10): 807-17.
    • (2008) Nat Rev Drug Discov , vol.7 , Issue.10 , pp. 807-817
    • Roses, A.D.1
  • 229
    • 33751103939 scopus 로고    scopus 로고
    • Adding pharmacogenetics information to drug labels: lessons learned
    • Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics 2006; 16(12): 847-54.
    • (2006) Pharmacogenet Genomics , vol.16 , Issue.12 , pp. 847-854
    • Haga, S.B.1    Thummel, K.E.2    Burke, W.3
  • 231
    • 69049114189 scopus 로고    scopus 로고
    • Pharmacogenomics of adverse drug reactions: practical applications and perspectives
    • Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 2009; 10(6): 961-9.
    • (2009) Pharmacogenomics , vol.10 , Issue.6 , pp. 961-969
    • Becquemont, L.1
  • 232
    • 0005248386 scopus 로고    scopus 로고
    • US Food and Drug Administration
    • FDA Approves Updated Warfarin (Coumadin) Prescribing Information
    • US Food and Drug Administration. FDA Approves Updated Warfarin (Coumadin) Prescribing Information. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm.
  • 233
    • 69349094274 scopus 로고    scopus 로고
    • FDA narrows drug label usage
    • Dolgin E. FDA narrows drug label usage. Nature 2009; 460(7259): 1069.
    • (2009) Nature , vol.460 , Issue.7259 , pp. 1069
    • Dolgin, E.1
  • 235
    • 77956249134 scopus 로고    scopus 로고
    • Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
    • Evaluation of Genomic Applications in Practice and Prevention (EGAPP). http://www.egappreviews. org/default.htm.
  • 238
    • 37349093041 scopus 로고    scopus 로고
    • Recommendations from the EGAPPWorking Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors
    • Recommendations from the EGAPPWorking Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007; 9(12): 819-25.
    • (2007) Genet Med , vol.9 , Issue.12 , pp. 819-252
  • 239
    • 59849117793 scopus 로고    scopus 로고
    • Recommendations from the EGAPPWorking Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    • Recommendations from the EGAPPWorking Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009; 11(1): 15-20.
    • (2009) Genet Med , vol.11 , Issue.1 , pp. 15-20
  • 241
    • 29544447266 scopus 로고    scopus 로고
    • TheAmpliChip CYP450 genotyping test: Integrating a newclinical tool
    • de Leon J, SusceMT, Murray-Carmichael E. TheAmpliChip CYP450 genotyping test: Integrating a newclinical tool. Mol Diagn Ther 2006; 10(3): 135-51.
    • (2006) Mol Diagn Ther , vol.10 , Issue.3 , pp. 135-151
    • de Leon, J.1    Susce, M.T.2    Murray-Carmichael, E.3
  • 242
    • 0005248386 scopus 로고    scopus 로고
    • US Food and Drug Administration
    • Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels
    • US Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
  • 244
    • 77952671414 scopus 로고    scopus 로고
    • Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients
    • Liu H, Wang C, Chen PH, Zhang BS, Zheng YL, Zhang CX, et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(4): 692-6.
    • (2010) Prog Neuropsychopharmacol Biol Psychiatry , vol.34 , Issue.4 , pp. 692-696
    • Liu, H.1    Wang, C.2    Chen, P.H.3    Zhang, B.S.4    Zheng, Y.L.5    Zhang, C.X.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.